Leith Wheeler Investment Counsel Ltd. Sells 509,821 Shares of Henry Schein, Inc. $HSIC

Leith Wheeler Investment Counsel Ltd. decreased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 95.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,336 shares of the company’s stock after selling 509,821 shares during the quarter. Leith Wheeler Investment Counsel Ltd.’s holdings in Henry Schein were worth $1,705,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Rakuten Securities Inc. bought a new stake in shares of Henry Schein in the 1st quarter valued at approximately $34,000. Steph & Co. bought a new stake in shares of Henry Schein in the 2nd quarter valued at approximately $44,000. CX Institutional grew its stake in shares of Henry Schein by 107.3% in the 2nd quarter. CX Institutional now owns 651 shares of the company’s stock valued at $48,000 after buying an additional 337 shares in the last quarter. TD Private Client Wealth LLC grew its stake in shares of Henry Schein by 103.0% in the 2nd quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock valued at $49,000 after buying an additional 339 shares in the last quarter. Finally, Whittier Trust Co. grew its stake in shares of Henry Schein by 714.3% in the 1st quarter. Whittier Trust Co. now owns 798 shares of the company’s stock valued at $55,000 after buying an additional 700 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a report on Wednesday, October 8th. Baird R W lowered Henry Schein from a “strong-buy” rating to a “hold” rating in a report on Monday, July 14th. Wall Street Zen lowered Henry Schein from a “buy” rating to a “hold” rating in a report on Saturday. Leerink Partners set a $75.00 target price on Henry Schein in a report on Monday, July 14th. Finally, Barrington Research restated an “outperform” rating and issued a $78.00 target price on shares of Henry Schein in a report on Tuesday, September 23rd. Five equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $76.67.

Henry Schein Stock Down 2.2%

Shares of HSIC stock opened at $63.17 on Monday. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The firm has a market cap of $7.66 billion, a PE ratio of 20.38, a price-to-earnings-growth ratio of 2.08 and a beta of 0.81. The stock has a 50 day moving average of $67.48 and a 200-day moving average of $68.80. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.09). Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.The business had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter last year, the firm earned $1.23 earnings per share. The firm’s quarterly revenue was up 3.3% compared to the same quarter last year. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, equities analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.